Top 10 Nephrology 2013 - Summaries

Four days left to vote for the top nephrology story of 2013. So far, the top 3 are:

1. The CORAL Trial
2. The Nephron-D Trial
3. JASN paper showing improved mortality for online HDF compared with standard HD.

The first two are not so surprising - high profile papers presented at the ASN and published in the NEJM. Even if they were negative trials, they have a significant impact and will change clinical practice. The third is more surprising to me personally although it is an important paper.

For a round up of pieces promoting various stories in this and other blogs:

• My own take on KIM1 and a piece on the uselessness of urinary eosinophils
• Andrew on UMOD, new targets for PKD and the new cholesterol guidelines
• Paul on Rituximab for ANCA-associated vasculitis
• Edgar on Nephron D at eAJKD
• Matt on APOL1 also at eAJKD
• Kenar at Nephron Power on Abatacept for FSGS
• Ed El Sayed at PBF also on Nephron D
• Joel on Tolvaptan in PKD at PBF
• Christos on HDPAL also at PBF
• Adrian on 23andMe at Red Beans
• Pascale on 23andMe at WhizBANG

Even if you don't feel like voting, this is a great set of summaries about some of the most important stories in nephrology for the year. Vote early and vote often